In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status

Darren Lau

doi:10.7326/J24-0025

In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status

Ann Intern Med. 2024 May;177(5):JC56. doi: 10.7326/J24-0025. Epub 2024 May 7.

Author

Darren Lau¹

Affiliation

¹ University of Alberta, Edmonton, Alberta, Canada (D.L.).

PMID: 38710083
DOI: 10.7326/J24-0025

Abstract

Kosiborod MN, Verma S, Borlaug BA, et al; STEP-HFpEF Trial Committees and Investigators. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204-216. 37952180.

Publication types

Randomized Controlled Trial

MeSH terms

Aged
Female
Glucagon-Like Peptides* / adverse effects
Glucagon-Like Peptides* / therapeutic use
Health Status
Heart Failure* / drug therapy
Humans
Male
Middle Aged
Obesity* / complications
Obesity* / drug therapy
Quality of Life*
Stroke Volume / drug effects
Weight Loss* / drug effects

Substances

semaglutide